Vitamin and Mineral Deficiencies: Vitamin D, B12, and Iron

1. Introduction

Micronutrient deficiencies represent a significant global health burden with profound implications for individual and public health. These conditions, characterized by suboptimal levels of essential vitamins and minerals, disrupt fundamental biochemical and physiological processes. Among the spectrum of potential deficiencies, those involving vitamin D, vitamin B12, and iron are particularly prevalent and clinically consequential across diverse populations. Their study is integral to medical and pharmaceutical education due to their high frequency, varied etiologies, and the critical role of pharmacological intervention in their management.

The historical understanding of these deficiencies has evolved from descriptions of classic deficiency syndromes—such as rickets, pernicious anemia, and chlorosis—to a contemporary appreciation of their subtler, subclinical manifestations and systemic effects. The identification of these essential nutrients and their roles in human physiology marked pivotal advances in biochemical and nutritional science.

From a pharmacological and medical perspective, the management of these deficiencies necessitates a thorough understanding of absorption kinetics, metabolic activation, storage dynamics, and the therapeutic use of replacement agents. Deficiencies can arise not only from inadequate intake but also from malabsorption syndromes, increased physiological demands, genetic polymorphisms affecting metabolism, and drug-nutrient interactions, making their study a multidisciplinary endeavor relevant to diagnostics, therapeutics, and preventive medicine.

Learning Objectives

• Define the biochemical roles, dietary sources, and recommended daily allowances for vitamin D, vitamin B12, and iron.
• Explain the pathophysiological mechanisms leading to deficiency states, including etiological factors related to intake, absorption, and utilization.
• Describe the clinical manifestations, diagnostic criteria, and laboratory assessment for deficiencies of vitamin D, B12, and iron.
• Compare and contrast the pharmacological properties, formulations, dosing strategies, and monitoring parameters for therapeutic replacement agents.
• Analyze clinical case scenarios to formulate appropriate assessment and management plans for patients with suspected or confirmed micronutrient deficiencies.

2. Fundamental Principles

The foundational principles governing micronutrient status revolve around concepts of homeostasis, bioavailability, and biochemical function. Vitamins and minerals act as essential cofactors, coenzymes, hormones, and structural components in myriad cellular processes. Deficiency states develop when the balance between supply, utilization, and loss is disrupted.

Core Concepts and Definitions

Vitamin D is a secosteroid hormone primarily synthesized in the skin via ultraviolet B radiation exposure to 7-dehydrocholesterol, with a minor contribution from dietary sources. It requires sequential hydroxylation in the liver (to 25-hydroxyvitamin D [25(OH)D]) and kidney (to 1,25-dihydroxyvitamin D [1,25(OH)₂D]) to become biologically active. Its principal function is the regulation of calcium and phosphate homeostasis to maintain bone mineralization.

Vitamin B12 (cobalamin) is a water-soluble vitamin containing cobalt, obtained exclusively from animal-derived foods. It is essential for two critical enzymatic reactions: the conversion of methylmalonyl-CoA to succinyl-CoA in mitochondrial metabolism, and the conversion of homocysteine to methionine in the cytoplasm, the latter being crucial for DNA synthesis and neurological function.

Iron is a transition metal vital for oxygen transport (as a component of hemoglobin and myoglobin) and cellular respiration (as a component of cytochromes and iron-sulfur clusters). Total body iron is tightly regulated, with no active excretory mechanism; balance is maintained primarily at the level of intestinal absorption.

Theoretical Foundations and Key Terminology

Understanding deficiency states requires familiarity with specific terminology. Status refers to the body’s total functional reserve of a nutrient. Biomarkers, such as serum 25(OH)D for vitamin D, serum B12 and methylmalonic acid (MMA) for B12, and serum ferritin for iron stores, are used to assess status. Bioavailability denotes the proportion of an ingested nutrient that is absorbed and utilized. Conditions like achlorhydria (lack of stomach acid) can impair B12 and iron absorption, while hepcidin, the master regulator of iron homeostasis, inhibits intestinal iron absorption and macrophage iron release in response to inflammation.

The enterohepatic circulation is particularly relevant for B12, which is actively reabsorbed in the ileum. For iron, the mucosal block theory describes how enterocyte iron levels regulate further absorption via modulation of ferroportin expression. The concept of functional deficiency is critical, where tissue levels are inadequate despite normal or borderline circulating levels, often identified by elevated metabolite levels like MMA or homocysteine for B12.

3. Detailed Explanation

An in-depth exploration of each deficiency reveals distinct yet interconnected physiological pathways, etiological factors, and diagnostic challenges.

Vitamin D Deficiency

Vitamin D’s synthesis and activation follow a multi-organ pathway. Cutaneous synthesis, which provides approximately 80% of requirement in sufficient sunlight, involves the conversion of 7-dehydrocholesterol to pre-vitamin D₃ under UVB light (290–315 nm), followed by thermal isomerization to vitamin D₃ (cholecalciferol). Dietary vitamin D (D₂ from plants, D₃ from animals) is incorporated into chylomicrons and absorbed in the small intestine. Both forms are transported to the liver bound to vitamin D-binding protein (DBP) and undergo 25-hydroxylation by cytochrome P450 enzymes (primarily CYP2R1). The resulting 25(OH)D is the major circulating form and the best indicator of overall status.

Final activation occurs in the renal proximal tubules via 1α-hydroxylase (CYP27B1), tightly regulated by parathyroid hormone (PTH), calcium, and phosphate levels. The active hormone, 1,25(OH)₂D, binds to the vitamin D receptor (VDR), a nuclear transcription factor that modulates gene expression in target tissues, primarily increasing intestinal calcium and phosphate absorption.

Deficiency is defined biochemically, though thresholds vary. A common classification is:

• Sufficiency: Serum 25(OH)D ≥ 20 ng/mL (50 nmol/L)
• Insufficiency: 12–20 ng/mL (30–50 nmol/L)
• Deficiency: < 12 ng/mL (< 30 nmol/L)

Severe deficiency (< 5 ng/mL) is associated with overt bone disease. Etiological factors are multifactorial:

Vitamin B12 Deficiency

The journey of vitamin B12 from ingestion to cellular utilization is complex and vulnerable to disruption at multiple points. Dietary cobalamin is bound to proteins in food. Gastric acid and pepsin in the stomach release it, allowing it to bind to R-proteins (haptocorrins) from saliva. In the duodenum, pancreatic proteases degrade the R-proteins, freeing B12 to bind with intrinsic factor (IF), a glycoprotein secreted by gastric parietal cells. The B12-IF complex is then actively absorbed by receptor-mediated endocytosis in the terminal ileum.

Within the enterocyte, B12 is released, bound to transcobalamin II (TCII), and released into the portal circulation. The TCII-B12 complex delivers the vitamin to cells. Two intracellular enzymatic reactions are B12-dependent. In the cytoplasm, methionine synthase requires methylcobalamin as a cofactor to transfer a methyl group from 5-methyltetrahydrofolate to homocysteine, generating methionine and tetrahydrofolate. In mitochondria, methylmalonyl-CoA mutase requires adenosylcobalamin to isomerize methylmalonyl-CoA to succinyl-CoA.

Deficiency thus leads to: 1) impaired DNA synthesis due to folate being “trapped” as 5-methyltetrahydrofolate, causing megaloblastic hematopoiesis; and 2) accumulation of homocysteine and methylmalonic acid (MMA), associated with neurotoxicity and vascular damage. Body stores (2–5 mg, primarily in the liver) are large relative to daily losses (1–3 µg), so deficiency typically develops over years once absorption ceases.

Etiologies are classically categorized:

• Pernicious Anemia: Autoimmune destruction of gastric parietal cells leading to lack of IF and achlorhydria.
• Malabsorption Syndromes: Ileal resection, Crohn’s disease, celiac disease, bacterial overgrowth (competing for B12).
• Dietary Deficiency: Strict veganism or long-term vegetarianism.
• Drug-Induced: Long-term use of proton pump inhibitors or histamine H2-receptor antagonists (reduce acid-mediated release from food); metformin (may alter ileal uptake).
• Genetic Disorders: Imerslund-Gräsbeck syndrome (defective ileal IF receptor).

Iron Deficiency

Iron metabolism is a closed, highly conserved system. The average adult contains 3–4 grams of iron, distributed as hemoglobin (≈65%), storage (ferritin and hemosiderin in liver, spleen, bone marrow; ≈30%), myoglobin (≈4%), and tissue/enzyme iron (≈1%). Daily losses from desquamation of skin and mucosal cells, and minor blood loss, total about 1–2 mg in men and non-menstruating women. This loss must be matched by absorption from the diet.

Dietary iron exists as heme iron (from hemoglobin and myoglobin in meat) and non-heme inorganic iron (from plants and fortified foods). Heme iron is absorbed more efficiently (15–35%) via a specific transporter (HCP1) in duodenal enterocytes. Non-heme iron absorption (2–20%) is influenced by luminal factors: ascorbic acid and meat enhance absorption, while phytates, polyphenols (in tea, coffee), calcium, and antacids inhibit it. Non-heme iron is reduced from ferric (Fe³⁺) to ferrous (Fe²⁺) by duodenal cytochrome b (Dcytb) before transport into the enterocyte via divalent metal transporter 1 (DMT1).

Intracellular iron is either stored as ferritin or exported into the circulation via ferroportin. Its export is coupled to oxidation back to Fe³⁺ by hephaestin and ceruloplasmin, after which it binds to transferrin for delivery to tissues. The key regulator is hepcidin, a peptide hormone synthesized in the liver. Hepcidin binds to ferroportin, causing its internalization and degradation, thus blocking iron egress from enterocytes, macrophages, and hepatocytes. Hepcidin synthesis is increased by high iron stores and inflammation (via interleukin-6), and decreased by erythropoietic demand, hypoxia, and iron deficiency.

Iron deficiency progresses through three stages:

1. Storage Depletion: Decreased bone marrow iron stores and serum ferritin, with normal hemoglobin and red cell indices.
2. Iron-Deficient Erythropoiesis: Exhausted stores lead to insufficient iron for hemoglobin synthesis. Serum iron falls, total iron-binding capacity (TIBC) rises, transferrin saturation decreases, and erythrocyte protoporphyrin increases. Hemoglobin remains normal.
3. Iron Deficiency Anemia (IDA): Frank microcytic, hypochromic anemia develops.

Primary causes include chronic blood loss (menorrhagia, GI bleeding), increased requirements (pregnancy, rapid growth), and inadequate intake or absorption (malnutrition, celiac disease, gastrectomy).

4. Clinical Significance

The clinical manifestations of these deficiencies extend beyond classic textbook descriptions, affecting multiple organ systems and contributing to chronic disease morbidity. Their relevance to drug therapy is bidirectional, encompassing both deficiency as a consequence of pharmacotherapy and the use of replacement agents as therapeutic interventions.

Relevance to Drug Therapy and Practical Applications

Vitamin D deficiency is associated with osteoporosis, increased fracture risk, muscle weakness, and falls. Pharmacologically, its correction is fundamental to the management of osteoporosis, often co-prescribed with calcium and antiresorptive or anabolic agents. Furthermore, vitamin D status may influence the response to certain therapies, and conversely, numerous drug classes can induce deficiency. Glucocorticoids, for instance, antagonize vitamin D-mediated calcium absorption and increase catabolism. Antiepileptic drugs (phenytoin, carbamazepine, phenobarbital) induce hepatic CYP450 enzymes that accelerate the catabolism of 25(OH)D and 1,25(OH)₂D. The practical application involves screening at-risk populations and providing adequate prophylactic or therapeutic supplementation.

Vitamin B12 deficiency has major neurological and hematological consequences. From a pharmacological standpoint, several widely used drugs can precipitate or exacerbate deficiency. Long-term proton pump inhibitor (PPI) therapy, by inducing achlorhydria, impedes the release of protein-bound B12 from food, though absorption of crystalline B12 (from supplements) remains intact. Metformin use has been associated with lower serum B12 levels, possibly due to altered intestinal motility and bacterial overgrowth or interference with the calcium-dependent IF-B12 complex absorption. Nitrous oxide anesthesia irreversibly oxidizes the cobalt core of cobalamin, inactivating methionine synthase; acute or repeated exposure can cause severe, acute neurological deterioration in individuals with subclinical deficiency. Therefore, assessing B12 status prior to elective surgery with nitrous oxide may be considered in high-risk patients.

Iron deficiency, particularly anemia, significantly impacts quality of life, cognitive function, and cardiovascular physiology. Its pharmacological relevance is vast. Iron deficiency can be a side effect of chronic therapy with anticoagulants (warfarin, DOACs) or antiplatelet agents due to occult bleeding. Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of gastritis and GI ulceration leading to blood loss. Conversely, oral iron therapy itself has significant drug interaction potential; it can bind to and reduce the absorption of concurrently administered levothyroxine, tetracycline antibiotics, fluoroquinolones, and bisphosphonates, necessitating dose separation by several hours. The management of iron deficiency in chronic inflammatory conditions (e.g., heart failure, chronic kidney disease) is complicated by functional iron deficiency, where hepcidin-driven sequestration limits the utility of oral iron, often requiring intravenous formulations.

Clinical Examples

A patient with long-standing rheumatoid arthritis on chronic NSAIDs and a glucocorticoid may present with multiple overlapping deficiencies: iron deficiency from GI blood loss, vitamin D deficiency from steroid-induced catabolism and reduced mobility/sun exposure, and possible B12 deficiency from drug-induced gastritis or concomitant autoimmune gastritis (associated with other autoimmune conditions). Another example is a post-bariatric surgery patient (Roux-en-Y gastric bypass) at high risk for deficiencies of all three nutrients due to anatomical alterations: reduced intake and bypass of the acidic stomach and B12/IF absorption site (duodenum and proximal ileum) leading to B12 and iron malabsorption, and often concomitant vitamin D deficiency due to malabsorption of fat-soluble vitamins.

5. Clinical Applications and Examples

The application of theoretical knowledge is best illustrated through structured clinical scenarios and problem-solving approaches.

Case Scenario 1: The Elderly Patient with Fatigue and Gait Instability

A 78-year-old woman presents with progressive fatigue, unsteady gait, and “pins and needles” in her feet for several months. She has a history of osteoarthritis managed with occasional ibuprofen and omeprazole 20 mg daily for “reflux” for over 5 years. Physical examination reveals pallor, mild glossitis, loss of vibration sense in the lower limbs, and a positive Romberg sign. Laboratory studies show: Hemoglobin 9.8 g/dL, MCV 110 fL, white blood cell count normal with hypersegmented neutrophils on smear. Reticulocyte count is low.

Problem-Solving Approach:

1. Interpret Hematological Findings: Macrocytic anemia with hypersegmented neutrophils is classic for megaloblastic anemia, most commonly caused by B12 or folate deficiency.
2. Integrate Neurological Symptoms: The presence of sensory neuropathy and gait ataxia strongly points towards B12 deficiency, as folate deficiency typically does not cause significant neurological sequelae.
3. Consider Etiology in Context: Long-term PPI use (omeprazole) is a known risk factor for food-bound B12 malabsorption. Furthermore, age increases the likelihood of atrophic gastritis or pernicious anemia. Ibuprofen use raises the possibility of concomitant iron deficiency from GI blood loss, which may be masked by the macrocytosis.
4. Diagnostic Confirmation: Key initial tests would include serum B12, folate, and methylmalonic acid (MMA) and homocysteine levels. A low B12 with elevated MMA and homocysteine confirms B12 deficiency. Anti-intrinsic factor and anti-parietal cell antibodies could be checked if pernicious anemia is suspected. Iron studies (ferritin, iron, TIBC) should also be performed.
5. Pharmacological Management: Treatment typically involves intramuscular hydroxocobalamin injections (e.g., 1000 µg daily for one week, then weekly for one month, then monthly) to bypass any absorption issues. High-dose oral cyanocobalamin (1000–2000 µg daily) may also be effective due to passive diffusion, but parenteral therapy is preferred initially in the presence of neurological symptoms. The PPI should be reviewed for ongoing necessity. A hematinic response (reticulocytosis in 5–7 days) and gradual neurological improvement are expected, though some deficits may be irreversible.

Case Scenario 2: The Young Woman with Menorrhagia and Bone Pain

A 32-year-old woman presents with persistent fatigue, exertional dyspnea, and diffuse bone pain. She reports heavy menstrual periods since menarche. She follows a strict vegan diet and works indoors. Examination reveals pale conjunctivae, koilonychia (spoon-shaped nails), and tenderness over the tibia. Initial labs: Hb 10.2 g/dL, MCV 78 fL, serum ferritin 8 ng/mL, 25-hydroxyvitamin D 14 ng/mL.

Problem-Solving Approach:

1. Identify the Deficiencies: Microcytic hypochromic anemia with very low ferritin confirms iron deficiency anemia. The low 25(OH)D level indicates concomitant vitamin D deficiency (insufficiency to deficiency range).
2. Establish Etiology: The most probable cause of iron deficiency is chronic blood loss from menorrhagia. The vegan diet is a major risk factor for both low iron intake (non-heme iron with poor bioavailability) and vitamin D deficiency (lack of fortified dairy, fish, eggs). Lack of sun exposure contributes to vitamin D deficiency.
3. Comprehensive Management Plan:
   • Iron Replacement: Oral ferrous sulfate 325 mg (providing 65 mg elemental iron) once or twice daily. Administration with vitamin C (e.g., orange juice) can enhance absorption. Counseled on GI side effects (constipation, nausea) and the need for prolonged therapy (3–6 months after hemoglobin normalizes to replenish stores).
   • Vitamin D Replacement: A repletion regimen such as ergocalciferol (D₂) or cholecalciferol (D₃) 50,000 IU weekly for 8–12 weeks, followed by maintenance dosing (e.g., 1000–2000 IU daily). Although D₃ is often considered more potent, both forms are effective in repletion regimens.
   • Address Underlying Cause: Referral to gynecology for management of menorrhagia is essential. Dietary counseling on iron-rich plant foods (lentils, spinach, fortified cereals) and vitamin D sources (fortified plant milks, mushrooms exposed to UV light) is required.
4. Monitoring: Hemoglobin and reticulocyte count should be checked in 2–4 weeks to assess response to iron. Ferritin and 25(OH)D levels should be rechecked after 3–4 months of therapy to confirm repletion and guide maintenance therapy.

Application to Specific Drug Classes

The management of deficiencies often intersects with other pharmacotherapies. For patients on levothyroxine for hypothyroidism who require iron, the drugs must be spaced at least 4 hours apart to prevent binding and reduced thyroxine absorption. In patients with chronic kidney disease (CKD) and anemia, the use of erythropoiesis-stimulating agents (ESAs) is ineffective without adequate iron availability. Here, intravenous iron (e.g., ferric carboxymaltose, iron sucrose) is frequently required due to functional iron deficiency and high hepcidin levels. For patients on anticoagulation therapy who develop iron deficiency, a thorough investigation for occult GI bleeding is mandatory before attributing it solely to menorrhagia or other obvious causes.

6. Summary and Key Points

The study of vitamin D, B12, and iron deficiencies provides a critical framework for understanding the intersection of nutrition, pathophysiology, and pharmacology.

Summary of Main Concepts

• Vitamin D, B12, and iron are essential micronutrients with distinct, complex pathways for absorption, metabolism, and physiological action.
• Deficiency states arise from a combination of inadequate intake, malabsorption, increased losses or demands, and drug-induced effects.
• Clinical manifestations are systemic: Vitamin D affects bone and muscle; B12 affects blood and the nervous system; Iron affects oxygen transport, energy metabolism, and multiple organ systems.
• Diagnosis relies on specific biomarkers: 25(OH)D for vitamin D status; serum B12, MMA, and homocysteine for B12 status; and a cascade of tests including ferritin, iron, TIBC, transferrin saturation, and hemoglobin for iron status.
• Pharmacological management involves replacement therapy with specific compounds (cholecalciferol/ergocalciferol, cyanocobalamin/hydroxocobalamin, various iron salts and complexes), with routes (oral, intramuscular, intravenous) and dosing strategies tailored to the severity, etiology, and clinical context of the deficiency.

Clinical Pearls

• Vitamin D deficiency is often asymptomatic until advanced; screening is warranted in high-risk groups (limited sun exposure, dark skin, elderly, malabsorption syndromes).
• Neurological symptoms of B12 deficiency can occur in the absence of anemia. A normal MCV does not rule out B12 deficiency, especially if coexisting with iron deficiency or thalassemia.
• Serum ferritin is the most specific indicator of iron stores but is an acute-phase reactant; a level > 100 ng/mL may be needed to exclude iron deficiency in the context of chronic inflammation.
• Oral iron is first-line for iron deficiency, but intravenous iron is indicated for intolerance, malabsorption, functional deficiency (e.g., in CKD, heart failure), or need for rapid repletion.
• Always investigate the underlying cause of a deficiency (e.g., GI workup for iron deficiency in men and postmenopausal women) rather than simply replacing the nutrient.
• Be vigilant for drug-nutrient interactions, both as a cause of deficiency (PPIs, metformin, anticonvulsants) and as a consequence of replacement therapy (iron binding other oral drugs).

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.